Replagal Antibody Response Should Be Studied Postmarketing, Cmte. Says

Concerns about antibody response to Transkaryotic Therapies' Replagal should be addressed in studies following accelerated approval, FDA's Endocrinologic & Metabolic Advisory Committee recommended Jan. 14